Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations

Table 1 Patient characteristics, n (%)

	RTCh	Ch	P value
	(n = 40)	(n = 27)
Age	60 (54-67)	67 (62-73)	0.32
Gender			0.29
Male	26 (65)	21 (77.8)
Performance status			0.21
ECOG 0	7 (17.5)	5 (18.5)
ECOG 1	33 (82.5)	20 (74.1)
ECOG 2	0	2 (7.4)
Smoking habit			0.48
Yes	20 (50)	15 (55.6)
No	2 (5)	3 (11.1)
Former smoker	18 (45)	9 (33.3)
Tumor localization			0.33
Apex	7 (17.5)	1 (3.7)
Right upper lobe	13 (32.5)	13 (48.1)
Right lower lobe	6 (15)	2 (7.4)
Left upper lobe	12 (30)	9 (33.3)
Left lower lobe	2 (5)	2 (7.4)
Histology			0.28
Adenocarcinoma	25 (62.5)	20 (74.1)
Squamous	13 (32.5)	6 (22.2)
NSCLC1	0	1 (3.7)
Large cell	2 (5)	0
Stage			0.52
IIIA	27 (67.5)	21 (77.8)
IIIB	12 (30)	6 (22.2)
IV	1 (2.5)	0
T			0.08
T1	4 (10)	9 (33.3)
T2	16 (40)	9 (33.3)
T3	10 (25)	7 (25.9)
T4	10 (25)	2 (7.4)
N			0.04
0	5 (12.5)	0
2	34 (85)	27 (100)
3	1 (2.5)	0
Metastasis	1 (2.5)	0	0.59
Nodal station distribution			0.012
N0	6 (15)	0
1N2	12 (30)	19 (70.4)
2N2	2 (5)	1 (3.7)
1N2 + 1N1	13 (32.5)	7 (25.9)
2N2 + 1N1	5 (12.5)	0
1N1 + 1N2 + 1N3	2 (5)	0
Nodal staging method			0.68
EBUS	24 (60)	14 (51.9)
Mediastinoscopy	2 (5)	3 (11.1)
EBUS and mediastinoscopy	8 (20)	6 (22.2)
EUS	1 (2.5)	2 (7.4)
None	5 (12.5)	2 (7.4)

¹Specific histology could not be determined in one patient. Ch: Chemotherapy. ECOG: Eastern Cooperative Group. NSCLC: Non-Small Cell Lung Cancer. RTCh: Radiochemotherapy; EUS: Endoscopic ultrasound; EBUS: Endobronchial ultrasound